|
TCEANC expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64235292032799E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.66022751102446E-12 |
| Normal-vs-Stage2 |
5.5946003385543E-10 |
| Normal-vs-Stage3 |
1.62525548574877E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
8.116500E-03 |
| Stage1-vs-Stage3 |
5.649500E-02 |
| Stage1-vs-Stage4 |
5.877900E-03 |
| Stage2-vs-Stage3 |
5.356200E-04 |
| Stage2-vs-Stage4 |
1.74403999999573E-05 |
| Stage3-vs-Stage4 |
2.284400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62925228863742E-12 |
| Normal-vs-AfricanAmerican |
1.77350356622696E-11 |
| Normal-vs-Asian |
6.50146603220492E-13 |
| Caucasian-vs-AfricanAmerican |
9.474600E-01 |
| Caucasian-vs-Asian |
2.288400E-01 |
| AfricanAmerican-vs-Asian |
4.800800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.66373598126302E-15 |
| Normal-vs-Female |
1.65345515057425E-12 |
| Male-vs-Female |
2.398400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63891122895166E-12 |
| Normal-vs-Age(41-60Yrs) |
1.6494583476856E-12 |
| Normal-vs-Age(61-80Yrs) |
2.27595720048157E-14 |
| Normal-vs-Age(81-100Yrs) |
4.25590000000531E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.752400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.987400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.905200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.155000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.616000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.488000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.4646000000027E-06 |
| Classical-VS-Follicular |
1.92140999999424E-05 |
| Classical-VS-Other |
4.703600E-01 |
| Classical-VS-Normal |
2.07611705604904E-14 |
| Tall-VS-Follicular |
1.39810385491046E-11 |
| Tall-VS-Other |
2.029600E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.554000E-02 |
| Follicular-VS-Normal |
1.03389996564118E-09 |
| Other-VS-Normal |
4.98849999974738E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.07944772512292E-12 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
2.04459999999518E-05 |
|
|
